Additional information
| Active substance | GLP-1 RA |
|---|---|
| Storage conditions | Store in a refrigerator at 2В°C to 8В°C (36В°F to 46В°F), protect from light |
| Side effects | Nausea, diarrhea, decreased appetite, vomiting, constipation |
| Effects | Improves glycemic control, promotes weight loss |
| Dosage (sports) | Not applicable as it is not used for performance enhancement |
| Dosage (medical) | Typically started at 2.5 mg once weekly, can be increased to 5 mg, 10 mg, or 15 mg once weekly depending on response and tolerability |
| Half-life | Approximately 5 days |
| Main action | Lowers blood glucose levels |
| Substance class | Glucagon-like peptide-1 (GLP-1) receptor agonists |
| Formula | C225H348N48O68 |
| Chemical name | Tirzepatide |
| Reference | CRX039 |
| ean13 | 1375214291544 |
| Dosage Unit | Ml |
| Milliliter Size | 4 Ml |
| FORM | Injection |
| Trade name | Mounjaro |
| Blood pressure | May reduce blood pressure |
| Also known as | LY3298176 |
| Lab Test | Monitoring blood glucose levels and HbA1c |
| Hepatotoxicity | No significant hepatotoxicity reported |
| Dosage | 5 Mg |
| Use in sports | None, not used for performance enhancement |
| Packing | Vial |
Reviews
There are no reviews yet.